12 de Octubre University Hospital
If you are the contact person for this centre and you wish to make any changes, please contact us.
Head of the Joint Cancer Immunotherapy Unit H12O/CNIO (Hospital Universitario 12 de Octubre/Centro Nacional de Investigaciones Oncológicas).
A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).
Approved therapies to treat various tumours using CAR-T cells are based on the modification of the patient's own lymphocytes in the laboratory, which delays their administration. A phase 1 clinical trial has used ready-made donor cells to treat patients with multiple myeloma. The results are published in the journal Nature Medicine.
Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.
Research published in the American Journal of Preventive Medicine has modelled the impact of ultra-processed food consumption on premature and preventable deaths in Brazil in 2019. According to the research, increased intake of these foods was associated with more than 10% of premature deaths in Brazil in 2019, representing about 57,000 deaths.